Premium
Meta‐analyses of studies of 0.2% delmopinol mouth rinse as an adjunct to gingival health and plaque control measures
Author(s) -
Addy Martin,
Moran John,
Newcombe Robert G.
Publication year - 2007
Publication title -
journal of clinical periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.456
H-Index - 151
eISSN - 1600-051X
pISSN - 0303-6979
DOI - 10.1111/j.1600-051x.2006.01013.x
Subject(s) - gingivitis , medicine , placebo , oral hygiene , dentistry , dental plaque , clinical trial , confidence interval , bleeding on probing , meta analysis , periodontitis , pathology , alternative medicine
Background: Delmopinol is a third‐generation anti‐plaque agent used as a mouthwash to reduce plaque and alleviate gingivitis. Objective: To create an overview of the anti‐plaque efficacy of 0.2% delmopinol as an adjunct to normal oral hygiene measures by meta‐analysis of completed clinical trials. Materials and Methods: Eight double‐blind, parallel‐group studies were identified. Study durations ranged from 8 to 24 weeks. Five studies ( n =913) involved supervised rinsing; three studies ( n =467) involved unsupervised rinsing. These sets of trials were analysed separately and in combination. Efficacy outcomes comprised modified plaque index, modified gingival index (MGI) and gingival bleeding on probing (BOP). Results: Delmopinol 0.2% was superior to placebo for the reduction of plaque scores in both sets of studies. Effects on MGI and BOP were also better with delmopinol 0.2% than with placebo. In most instances, 95% confidence intervals were wholly in favour of delmopinol. Pooled analysis of all eight studies confirmed statistically significant effects of delmopinol 0.2% compared with placebo ( p <0.00001). Delmopinol met the efficacy criteria of the American Dental Association in studies of extended duration. Conclusion: Delmopinol 0.2% mouthwash is effective as an adjunct measure for reducing plaque burden and indices of gingivitis, whether or not it is used under supervision.